# NVO — slm-full-gpu

## Metadata

ticker: NVO
arm: slm-full-gpu
judge_prompt_version: v2
context_sha256: e93aa0fbdb2ee6507b16a844029cec24c8eb01125cf30430ead70682667bfe4e
slm_endpoint: slm-gpu
slm_url: http://132.145.161.150:30880
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 5
llm_endpoints: slm-gpu
llm_by_site: {"section:financial_health": {"calls": 1, "completion_tokens": 160, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.059, "latency_s_total": 4.059, "parse_failure": 0, "prompt_tokens": 375, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 147, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 3.869, "latency_s_total": 3.869, "parse_failure": 0, "prompt_tokens": 369, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 161, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.071, "latency_s_total": 4.071, "parse_failure": 0, "prompt_tokens": 365, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 73, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.687, "latency_s_total": 2.687, "parse_failure": 0, "prompt_tokens": 373, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 844, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 9.194, "latency_s_total": 9.194, "parse_failure": 0, "prompt_tokens": 1518, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "NVO",
  "company_name": "Novo Nordisk A/S",
  "current_price": 37.54,
  "currency": "USD",
  "market_cap": 165760876544.0,
  "pe_ratio": 9.178484,
  "forward_pe": 11.285312,
  "week_52_high": 64.16,
  "week_52_low": 35.12,
  "financial_currency": "DKK",
  "revenue": 329430990848.0,
  "net_income": 116442996736.0,
  "profit_margin_pct": 35.35,
  "dividend_yield": 4.79,
  "sector": "Healthcare",
  "industry": "Drug Manufacturers - General"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "message": "No 10-K found"
  },
  "10-Q": {
    "message": "No 10-Q found"
  }
}

RAG — SEC HIGHLIGHTS:
(not available)

RAG — RISK FACTORS:
(not available)

## Pre-written sections (judge input)

### Financial Health

Novo Nordisk A/S trades at $37.54 with a market capitalization of approximately $165.76 billion, reflecting a compelling valuation with a P/E ratio of 9.18. The company demonstrates exceptional profitability, generating DKK 329.43 billion in revenue and DKK 116.44 billion in net income, resulting in a robust profit margin of 35.35%. This strong financial performance, combined with a forward P/E of 11.29, indicates solid earnings power relative to its current price. The stock is currently near its 52-week low of $35.12, suggesting potential value for investors seeking exposure to high-margin healthcare assets.

### Recent Developments

Novo Nordisk continues to demonstrate robust financial health, reporting a net income of DKK 116.44 billion on revenues of DKK 329.43 billion, underscoring strong operational execution. The company maintains an attractive dividend yield of 4.79%, providing steady income potential for shareholders amidst market volatility. With a current price near the 52-week low of USD 35.12, the stock presents a potential valuation opportunity relative to its historical highs and solid profit margins of 35.35%. Investors should monitor upcoming clinical data and supply chain expansions as key catalysts for future growth in the competitive GLP-1 market.

### SEC Filing Highlights
No recent 10-K or 10-Q filings were available for Novo Nordisk A/S (NVO) in the current dataset. Consequently, specific operational or financial disclosures from the most recent quarterly or annual report cannot be summarized. Investors are advised to consult the company’s official investor relations page for the latest regulatory submissions.

### Risk Factors
*   **Regulatory and Pricing Pressure:** Potential for government-imposed price caps or reimbursement restrictions on GLP-1 therapies (e.g., Ozempic, Wegovy) in key markets like the US and EU, which could compress the current 35.35% profit margin.
*   **Competitive Landscape:** Intensifying competition from rivals such as Eli Lilly (Mounjaro/Zepbound) and emerging biosimilars may erode Novo Nordisk’s market share and slow revenue growth in the lucrative obesity and diabetes sectors.
*   **Supply Chain and Execution Risks:** High demand for injectable medications requires complex manufacturing and supply chain execution; any production bottlenecks or quality control issues could limit sales capacity and damage brand reputation.

## Audited (Exec Summary + Outlook)

### Executive Summary
Novo Nordisk A/S is a dominant force in the GLP-1 market, leveraging its leadership in diabetes and obesity treatments to generate DKK 329.43 billion in revenue and DKK 116.44 billion in net income, supported by a robust 35.35% profit margin. The stock is currently notable for trading near its 52-week low of $35.12, presenting a potential value opportunity relative to its strong earnings power and attractive 4.79% dividend yield. The single most important near-term variable shaping the investment outcome is the company’s ability to manage supply chain execution and navigate intensifying competitive pressures from rivals like Eli Lilly.

### Outlook
The directional outlook for Novo Nordisk is cautiously constructive, driven by the enduring structural demand for GLP-1 therapies and the company’s strong cash generation capabilities. Key variables to monitor include the pace of supply chain expansion, which is critical to meeting unmet demand, and the evolving competitive dynamics with emerging rivals. The thesis would be strengthened by sustained clinical data validation and successful market penetration in new indications, while it would be weakened by significant regulatory pricing headwinds or execution failures that constrain sales capacity. Investors should focus on operational resilience and margin stability rather than short-term valuation multiples.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the Executive Summary and Outlook sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "DKK 329.43 billion in revenue"
LABEL: SUPPORTED
REASON: The source data shows revenue of 329,430,990,848 DKK, which rounds to DKK 329.43 billion, and this figure is explicitly restated in the pre-written Financial Health and Recent Developments sections.

---

CLAIM: "DKK 116.44 billion in net income"
LABEL: SUPPORTED
REASON: The source data shows net income of 116,442,996,736 DKK, which rounds to DKK 116.44 billion, and this figure is explicitly restated in the pre-written sections.

---

CLAIM: "robust 35.35% profit margin"
LABEL: SUPPORTED
REASON: The source data explicitly lists profit_margin_pct as 35.35, and this figure is confirmed in the pre-written sections.

---

CLAIM: "trading near its 52-week low of $35.12"
LABEL: SUPPORTED
REASON: The source data lists week_52_low as $35.12 and current_price as $37.54; $37.54 is approximately 6.9% above the 52-week low, which is consistent with "near its 52-week low," and the $35.12 figure is explicitly present in the source data.

---

CLAIM: "attractive 4.79% dividend yield"
LABEL: SUPPORTED
REASON: The source data explicitly lists dividend_yield as 4.79.

---

**OUTLOOK**

The Outlook section contains no specific quantitative figures, price targets, thresholds, ratios, metrics, percentages, named product milestones, or forward-looking numbers. All statements are qualitative and directional in nature (e.g., "cautiously constructive," "enduring structural demand," "strong cash generation capabilities," "sustained clinical data validation"). There are therefore no quantitative or forward-looking numerical claims in the Outlook section to audit.

---

**SUMMARY TABLE**

| Claim | Label |
|---|---|
| DKK 329.43 billion in revenue | SUPPORTED |
| DKK 116.44 billion in net income | SUPPORTED |
| 35.35% profit margin | SUPPORTED |
| 52-week low of $35.12 | SUPPORTED |
| 4.79% dividend yield | SUPPORTED |

All five auditable quantitative claims in the Executive Summary are fully supported by the source data. The Outlook section contains no quantitative claims requiring audit.
